Treatment of both A549 and H1299 lung cancer cells with GSPs for 48 h resulted in a significantly higher (p<0.05; p<0.001) caspase-3 activity in a dose-dependent manner than that observed in the vehicle-treated control cells (Figure 3B). The gene discussed is CASP3; the disease is lung carcinoma.